Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 647.19

+0.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

CuttingEdge Bio

To: Biotechwantabe who wrote (3125)	10/29/2020 2:49:56 AM
From: Miljenko Zuanic	1 Recommendation Read Replies (1) of 3557

From Sanofi, 3Q-2020 "Dupixent® (collaboration with Regeneron) generated sales of €918 million in the third quarter (up 68.6%). In the U.S., Dupixent® sales of €725 million (up 67.7%) were ..." E= 1.17$, --->US $848M, which is in line with my projection. (and 10% growth, QvQ) Ex-US= $226M, 30% growth QvQ (picking up some speed) Europe =97e Japan =48e sanofi.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next